{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:42Z","timestamp":1788026322470,"version":"build-2784847793"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40259-024-00668-z","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:01:32Z","timestamp":1722391292000},"page":"681-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct04893707","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Feng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Ren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Chun","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Juan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao-Ran","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Min","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Zhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"3","key":"668_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.det.2017.02.006","volume":"35","author":"K Malik","year":"2017","unstructured":"Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017;35(3):317\u201326. https:\/\/doi.org\/10.1016\/j.det.2017.02.006.","journal-title":"Dermatol Clin"},{"issue":"2","key":"668_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","volume":"138","author":"T Werfel","year":"2016","unstructured":"Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336\u201349. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"668_CR3","doi-asserted-by":"publisher","first-page":"CD012119","DOI":"10.1002\/14651858","volume":"2","author":"EJ van Zuuren","year":"2017","unstructured":"van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. https:\/\/doi.org\/10.1002\/14651858.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"668_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343. https:\/\/doi.org\/10.1056\/NEJMra2023911.","journal-title":"N Engl J Med"},{"issue":"2","key":"668_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.19580","volume":"184","author":"MR Laughter","year":"2021","unstructured":"Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990\u20132017. Br J Dermatol. 2021;184(2):304\u20139. https:\/\/doi.org\/10.1111\/bjd.19580.","journal-title":"Br J Dermatol"},{"issue":"2","key":"668_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","volume":"123","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144\u201351. https:\/\/doi.org\/10.1016\/j.anai.2019.04.020.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"668_CR7","doi-asserted-by":"publisher","unstructured":"Yao X, Song ZQ, Li W, Liang YS, Zhao Y, Cao H, et al. Guidelines for diagnosis and treatment of atopic dermatitis in China (2020). Int J Dermatol Venereol. 2021;4(1):1\u20139. https:\/\/doi.org\/10.1097\/JD9.0000000000000143.","DOI":"10.1097\/JD9.0000000000000143"},{"issue":"5","key":"668_CR8","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","volume":"151","author":"CF Schuler","year":"2023","unstructured":"Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1145\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"668_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21\u201340. https:\/\/doi.org\/10.1038\/s41573-021-00266-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"10023","key":"668_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/s0140-6736(15)00149-x","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322. https:\/\/doi.org\/10.1016\/s0140-6736(15)00149-x.","journal-title":"Lancet"},{"issue":"3","key":"668_CR11","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2133.2009.09561.x","volume":"162","author":"J Schmitt","year":"2010","unstructured":"Schmitt J, Sch\u00e4kel K, F\u00f6lster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs. ciclosporin for severe adult eczema: an investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162(3):661\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09561.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"668_CR12","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519\u201331. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.005.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"668_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. J Am Acad Dermatol. 2014;71(2):327\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.030.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"668_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378. https:\/\/doi.org\/10.1111\/jdv.14888.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"668_CR15","unstructured":"US Food and Drug Administration. Dupixent (dupilumab) injection [package insert]. June 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Accessed 19 Aug 2019."},{"key":"668_CR16","unstructured":"European Medicines Agency. Summary of product characteristics: adtralza 150 mg solution for injection in pre-filled syringe. 2021. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210617151835\/anx_151835_en.pdf. Accessed 28 June 2021."},{"key":"668_CR17","unstructured":"Leo Pharma A\/S. LEO Pharma announces European Commission approval of Adtralza\u00ae (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis [media release]. 22 Jun 2021. https:\/\/www.leo-pharma.com\/. Accessed 24 June 2024."},{"issue":"1","key":"668_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139\u201347. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.051.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"668_CR19","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/jdv.19382","volume":"38","author":"E Pezzolo","year":"2024","unstructured":"Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, et al. Survival, efficacy and safety of tralokinumab after 32 and 52\u00a0weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. 2024;38(1):e11\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"668_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102076","volume":"61","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yan B, Shen S, Song X, Jiang Y, Shi L, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023;61: 102076. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102076.","journal-title":"EClinicalMedicine"},{"key":"668_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102467","volume":"69","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yan B, Zhu Z, Wang X, Song X, Zhu D, et al. Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial. EClinicalMedicine. 2024;69: 102467. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102467.","journal-title":"EClinicalMedicine"},{"key":"668_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002747","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhang J, Yang B, Li J, Ding Y, Wu L, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial. Chin Med J (Engl). 2023. https:\/\/doi.org\/10.1097\/cm9.0000000000002747.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"668_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","volume":"77","author":"JP Thyssen","year":"2017","unstructured":"Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280-6.e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.003.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"668_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373. https:\/\/doi.org\/10.1111\/bjd.17869.","journal-title":"Br J Dermatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00668-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00668-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00668-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T20:24:33Z","timestamp":1724876673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00668-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00668-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"16 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Keymed Biosciences (Chengdu) Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jiao-Ran Song, Ying-Min Jia, Li-Bo Zhang, and Bo Chen are employees of Keymed Biosciences (Chengdu) Co., Ltd. Yan Zhao, Jing-Yi Li, Bin Yang, Yang-Feng Ding, Li-Ming Wu, Li-Tao Zhang, Jin-Yan Wang, Qian-Jin Lu, Chun-Lei Zhang, Fu-Ren Zhang, Xiao-Hong Zhu, Yu-Mei Li, Xiao-Hua Tao, Qing-Chun Diao, Lin-Feng Li, Jian-Yun Lu, Xiao-Yong Man, Fu-Qiu Li, Xiu-Juan Xia, and Jian-Zhong Zhang have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This trial was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and relevant regulations. The protocol was approved by the Institutional Review Board and independent Ethics Committee of the Peking University People\u2019s Hospital (No. 2021PHA021-007) and the participating study centers.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Concept and design: JZ, YZ, BC, YJ. Drafting of the manuscript: YZ, YJ, JS. Statistical analysis: LZ. All authors contributed to the acquisition, analysis, and interpretation of data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}